Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain

Pharmacogenomics

Volumn 15, Issue 4, 2014, Pages 423-431

  Brandl, Eva J ^a,b   Tiwari, Arun K ^a   Chowdhury, Nabilah I ^a,b   Zai, Clement C ^a,b   Lieberman, Jeffrey A ^c   Meltzer, Herbert Y ^d   Kennedy, James L ^a,b   Müller, Daniel J ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Psychiatry College of Physicians and Surgs Columbia University and the New York State Psychiatric Institute ^*  (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

antipsychotic induced weight gain; clozapine; GCG; GLP1R; olanzapine; pharmacogenetics

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; NEUROLEPTIC AGENT;

3' UNTRANSLATED REGION; ADULT; ANTIPSYCHOTIC INDUCED WEIGHT GAIN; ARTICLE; BODY WEIGHT DISORDER; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GCG GENE; GENE EXPRESSION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLP1R GENE; GLUCOSE METABOLISM; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PHARMACOGENETICS; SCHIZOPHRENIA; TREATMENT DURATION; TREND STUDY; WEIGHT CHANGE; CAUCASIAN; DRUG EFFECTS; GENETICS; GENOTYPE; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, GLUCAGON; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84896334203     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.247     Document Type: Article

References (49)

1. Gallini A, Donohue JM, Huskamp HA. Diffusion of antipsychotics in the U.S. and French Markets, 1998-2008. Psychiatr. Serv. (2013).
2. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156(11), 1686-1696 (1999).
3. Lipkovich I, Jacobson JG, Caldwell C, Hoffmann VP, Kryzhanovskaya L, Beasley CM. Early predictors of weight gain risk during treatment with olanzapine: ana lysis of pooled data from 58 clinical trials. Psychopharmacol. Bull. 42(4), 23-39 (2009).
4. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 43(6), 620-626 (2009).
5. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 17(3), 242-266 (2012).
6. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7(6), 863-887 (2006).
7. Sicard MN, Zai CC, Tiwari AK et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11(11), 1561-1571 (2010).
8. De Luca V, Muller DJ, Hwang R et al. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum. Psychopharm. 22(7), 463-467 (2007).
9. Brandl EJ, Frydrychowicz C, Tiwari AK et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 38(2), 134-141 (2012).
10. Malhotra AK, Correll CU, Chowdhury NI et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatr 69(9), 904-912 (2012).
11. Brandl EJ, Tiwari AK, Lett TA et al. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Hum. Psychopharmacol. 28(2), 183-187 (2013).
12. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136(8), 3585-3596 (1995).
13. Phillips LK, Prins JB. Update on incretin hormones. Ann. N. Y. Acad. Sci. 1243, E55-74 (2011).
14. Burmeister MA, Ayala J, Drucker DJ, Ayala JE. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am. J. Physiol. Endocr. Metab. 304(7), E677-E685 (2013).
15. Poleni PE, Akieda-Asai S, Koda S et al. Possible involvement of melanocortin-4-receptor and AMP-activated protein kinase in the interaction of glucagon-like peptide-1 and leptin on feeding in rats. Biochem. Biophys. Res. Commun. 420(1), 36-41 (2012).
16. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr. Diabetes Rev. 9(1), 25-53 (2013).
17. Herzberg-Schafer S, Heni M, Stefan N, Haring HU, Fritsche A. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes Obes. Metab. 14(Suppl. 3), 85-90 (2012).
18. Li Y, Perry T, Kindy MS et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl Acad. Sci. USA 106(4), 1285-1290 (2009).
19. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 26(10), 871-882 (2012).
20. Holst JJ, Christensen M, Lund A et al. Regulation of glucagon secretion by incretins. Diabetes Obes. Metab. 13(Suppl. 1), 89-94 (2011).
21. Dixit TS, Sharma AN, Lucot JB, Elased KM. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol. Behav. 114-115, 38-41 (2013).
22. Smith GC, Vickers MH, Shepherd PR. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch. Physiol. Biochem.117(4), 241-249 (2011).
23. Smith GC, Vickers MH, Cognard E, Shepherd PR. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr. Res. 115(1), 30-40 (2009).
24. van der Zwaal EM, Merkestein M, Lam YK et al. The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature. Int. J. Obes. (Lond.) 36(2), 254-261 (2012).
25. Vidarsdottir S, Roelfsema F, Streefand T, Holst JJ, Rehfeld JF, Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur. J. Endocrinol. 162(1), 75-83 (2010).
26. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr. Res. 103(1-3), 94-103 (2008).
27. Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with Type 2 diabetes after short-term treatment. Diabetes Obes. Metab. 15(10), 958-962 (2013).
28. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012).
29. Astrup A, Carraro R, Finer N et al. Sa fet y, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. (Lond.) 36(6), 843-854 (2012).
30. Ebdrup BH, Knop FK, Ishoy PL et al. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefts. BMC Med. 10, 92 (2012).
31. Torekov SS, Ma L, Grarup N et al. Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1. Diabetologia 54(11), 2820-2831 (2011).
32. Sheikh HI, Dougherty LR, Hayden EP, Klein DN, Singh SM. Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(6), 980-983 (2010).
33. Sathananthan A, Man CD, Micheletto F et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care 33(9), 2074-2076 (2010).
34. Kumar KG, Poole AC, York B, Volaufova J, Zuberi A, Richards BK. Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confrmation and candidate gene analyses (Glo1, Glp1r). Am. J. Physiol. Regul. Integr. Comp. Physiol. 292(1), R207-R216 (2007).
35. Kumar KG, Byerley LO, Volaufova J et al. Genetic variation in Glp1r expression infuences the rate of gastric emptying in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294(2), R362-R371 (2008).
36. Scrocchi LA, Brown TJ, Maclusky N et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2(11), 1254-1258 (1996).
37. Tiwari AK, Rodgers JB, Sicard M et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(8), 1484-1490 (2010).
38. Tiwari AK, Zai CC, Likhodi O et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 35(6), 1315-1324 (2010).
39. Tiwari AK, Brandl EJ, Weber C et al. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J. Clin. Psychopharmacol. 33(1), 11-17 (2013).
40. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19(19), 5444 (1991).
41. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: ana lysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
42. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25(2), 115-121 (2003).
43. Calle ML, Urrea V, Malats N, van Steen K. mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. Bioinformatics 26(17), 2198-2199 (2010).
44. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74(4), 765-769 (2004).
45. Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies? Nat. Rev. Genet. 5(8), 618-625 (2004).
46. Dunham I, Kundaje A, Aldred SF et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012).
47. Stephan M, Radicke A, Leutloff S et al. Dipeptidyl peptidase IV (DPP4)-defciency attenuates diet-induced obesity in rats: possible implications for the hypothalamic neuropeptidergic system. Behav. Brain Res. 216(2), 712-718 (2011).
48. Yagi T, Nishi S, Hinata S, Murakami M, Yoshi m i T. A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with Type 2 diabetes and impaired glucose tolerance in Japanese subjects. Diabet. Med. 13(10), 902-907 (1996).
49. Laukkanen O, Lindstrom J, Eriksson J et al. Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to Type 2 diabetes: the Finnish diabetes prevention study. Diabetes 54(7), 2256-2260 (2005).